Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hormone therapy plus precision radiation aims to crush prostate cancer early

NCT ID NCT06067269

Recruiting now Disease control Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This trial investigates whether adding the hormone therapy apalutamide to high-precision radiation (SBRT) can drive prostate-specific antigen (PSA) levels extremely low in men with intermediate-risk prostate cancer. Participants receive apalutamide to block testosterone that fuels tumor growth, along with image-guided SBRT that delivers focused radiation in fewer sessions. The goal is to see if this combination leads to better early disease control compared to historical outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a hormone therapy called apalutamide combined with image-guided stereotactic body radiation therapy (SBRT)
What this could lead to
If successful, this combination could offer a more effective, shorter course of treatment for intermediate-risk prostate cancer, potentially improving long-term disease control.
What could go wrong
This is a phase 2 trial with a moderate number of participants, so results are not definitive. The added hormone therapy may cause side effects, and the approach may not prove better than standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE ADENOCARCINOMA STAGE II PROSTATE CANCER AJCC V8 STAGE IIIA PROSTATE CANCER AJCC V8 STAGE IIIB PROSTATE CANCER AJCC V8

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UCLA / Jonsson Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90095, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.